# LQDA catalysts: Liquidia Corp PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/lqda/catalysts

> Liquidia Corp (LQDA) has 5 upcoming catalysts. The next is the liq861 (treprostinil) inhalation powder - dose titration arm primary completion, February 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Liquidia Corp |
| Ticker | LQDA (Nasdaq) |
| SEC CIK | 1819576 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/lqda |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Jul 2023 | [YUTREPIA (treprostinil) NDA/BLA submission](https://sec-api.dev/pdufa/treprostinil) | LQDA |  | completed | "In July 2023, we filed an amendment to our NDA to add PH-ILD to the labeled indications for YUTREPIA." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1819576/000155837025003237/lqda-20241231x10k.htm)) |
| Sep 2024 | [YUTREPIA (treprostinil) NDA/BLA acceptance](https://sec-api.dev/pdufa/treprostinil) | LQDA |  | completed | "In September 2024, United Therapeutics filed a cross claim in the New FDA Litigation, re-asserting its challenge to FDA's acceptance of the Company's amended NDA for review." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819576/000155837025006838/lqda-20241231xex99d1.htm)) |
| September 16, 2024 | [Liquidia Corp NDA/BLA acceptance](https://sec-api.dev/companies/lqda/catalysts) | LQDA |  | completed | "On September 16, 2024, United Therapeutics filed a cross claim in the New FDA Litigation, re-asserting its challenge to FDA's acceptance of the Company's amended NDA for review." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1819576/000155837024015433/lqda-20240930x10q.htm)) |
| November 13, 2024 | [Liquidia Corp earnings report](https://sec-api.dev/companies/lqda/catalysts) | LQDA |  | completed | "Corporation Reports Third Quarter 2024 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819576/000110465924117193/tm2428261d1_ex99-1.htm)) |
| March 19, 2025 | [Liquidia Corp earnings report](https://sec-api.dev/companies/lqda/catalysts) | LQDA |  | completed | "Reports Full Year 2024 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819576/000110465925025326/tm259683d1_ex99-1.htm)) |
| March 28, 2025 | [YUTREPIA (treprostinil) NDA/BLA acceptance](https://sec-api.dev/pdufa/treprostinil) | LQDA | rare cardiopulmonary disease, today | completed | "As previously disclosed on March 28, 2025, the FDA has accepted the Company's NDA resubmission for YUTREPIA to treat pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease and has set a Prescription Drug User Fee Act ("PDUFA") goal date of May 24, 2025." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1819576/000110465925044345/tm2514002d1_8k.htm)) |
| May 8, 2025 | [Liquidia Corp earnings report](https://sec-api.dev/companies/lqda/catalysts) | LQDA |  | completed | "Corporation Reports First Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819576/000110465925045850/tm2514389d1_ex99-1.htm)) |
| May 23, 2025 | [YUTREPIA (treprostinil) FDA approval](https://sec-api.dev/pdufa/treprostinil) | LQDA | PAH and PH-ILD in May 2025 | completed, approved | "As previously disclosed, the FDA granted approval of YUTREPIA™ for the treatment of PAH and PH-ILD on May 23, 2025." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1819576/000110465925055180/tm2516834d1_8k.htm)) |
| May 24, 2025 | [YUTREPIA (treprostinil) PDUFA date](https://sec-api.dev/pdufa/treprostinil) | LQDA |  | completed, approved | "Does not impact FDA's ability to take final action on NDA for YUTREPIA on PDUFA goal date of May 24, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819576/000110465925046935/tm2514743d1_ex99-1.htm)) |
| May 24, 2025 | [DPI (dpi) PDUFA date](https://sec-api.dev/pdufa/dpi) | LQDA |  | scheduled | "The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of May 24, 2025, the day after regulatory exclusivity expires for Tyvaso DPI®." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819576/000110465925045850/tm2514389d1_ex99-1.htm)) |
| May 2025 | [Liq861 inhaled treprostinil primary completion](https://sec-api.dev/pdufa/liq861-inhaled-treprostinil) | LQDA | Primary Pulmonary Hypertension | delayed | "NCT03992755 (Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-05-31 (ESTIMATED); Lead Sponsor Liquidia Technologies, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03992755)) |
| August 12, 2025 | [Liquidia Corp earnings report](https://sec-api.dev/companies/lqda/catalysts) | LQDA |  | completed | "2025 - Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases, today announced its financial results for the second quarter ended June 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819576/000110465925076412/tm2523179d1_ex99-1.htm)) |
| November 3, 2025 | [Liquidia Corp earnings report](https://sec-api.dev/companies/lqda/catalysts) | LQDA |  | completed | "N.C., November 3, 2025 - Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced its financial results for the third quarter ended September 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819576/000110465925105199/tm2530004d1_ex99-1.htm)) |
| Mar 2026 | [Uptravi (selexipag) topline data readout](https://sec-api.dev/pdufa/selexipag) | LQDA | PAH, such | completed, positive | "IP-agonists to treat PAH, such as the oral formulations of selexipag, marketed by Actelion, and ralinepag, being developed by UTC, who announced positive top-line Phase 3 results in March 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1819576/000110465926124752/lqda-20260930x10q.htm)) |
| March 5, 2026 | [Liquidia Corp earnings report](https://sec-api.dev/companies/lqda/catalysts) | LQDA |  | completed | "Liquidia Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819576/000110465926023794/tm267579d3_ex99-1.htm)) |
| May 11, 2026 | [Liquidia Corp earnings report](https://sec-api.dev/companies/lqda/catalysts) | LQDA |  | completed | "N.C., May 11, 2026 - Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today reported financial results for the first quarter ended March 31, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819576/000110465926058234/tm2614109d1_ex99-1.htm)) |
| 2H 2026 | [Liquidia Corp topline data readout](https://sec-api.dev/companies/lqda/catalysts) | LQDA |  | scheduled | "Topline data from an on-going Phase 2 study is expected in the second half of 2026." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1819576/000110465926023804/lqda-20251231x10k.htm)) |
| August 12, 2026 | [Liquidia Corp earnings report](https://sec-api.dev/companies/lqda/catalysts) | LQDA |  | completed | "N.C., August 12, 2026 - Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today reported financial results for the second quarter ended June 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819576/000110465926094411/tm2622888d1_ex99-1.htm)) |
| Q4 2026 | [YUTREPIA (treprostinil) trial start](https://sec-api.dev/pdufa/treprostinil) | LQDA |  | scheduled | "Liquidia plans to initiate RE-WARM, a Phase 2a dose-finding study of YUTREPIA in SSc-RP, in the fourth quarter of 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819576/000110465926104929/tm2624724d1_ex99-1.htm)) |
| November 10, 2026 | [Liquidia Corp earnings report](https://sec-api.dev/companies/lqda/catalysts) | LQDA |  | completed | "- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today reported financial results for the third quarter ended September 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819576/000110465926124770/tm2629427d1_ex99-1.htm)) |
| February 2027 | [Liq861 (treprostinil) inhalation powder - dose titration arm primary completion](https://sec-api.dev/pdufa/liq861-treprostinil-inhalation-powder-dose-titration-arm) | LQDA | Raynaud's Phenomenon Secondary to Systemic Sclerosis | scheduled | "NCT07748000 (A Study of LIQ861 (Inhaled Treprostinil) in Adults With Systemic Sclerosis Who Have Symptomatic Raynaud's Phenomenon Attacks): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2027-02 (ESTIMATED); Lead Sponsor Liquidia Technologies, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07748000)) |
| Feb to May 2027 | [Liq861 (treprostinil) inhalation powder - dose titration arm topline data readout](https://sec-api.dev/pdufa/liq861-treprostinil-inhalation-powder-dose-titration-arm) | LQDA | Raynaud's Phenomenon Secondary to Systemic Sclerosis | scheduled | "NCT07748000 (A Study of LIQ861 (Inhaled Treprostinil) in Adults With Systemic Sclerosis Who Have Symptomatic Raynaud's Phenomenon Attacks): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2027-02 (ESTIMATED); Lead Sponsor Liquidia Technologies, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07748000)) |
| June 24, 2027 | [Liquidia Corp PDUFA date](https://sec-api.dev/companies/lqda/catalysts) | LQDA |  | scheduled | "In August 2026, the FDA accepted the NDA for ralinepag to treat PAH and set a PDUFA target action date of June 24, 2027." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1819576/000110465926124752/lqda-20260930x10q.htm)) |
| July 2029 | [L606 primary completion](https://sec-api.dev/pdufa/l606) | LQDA | Pulmonary Hypertension Due to Lung Disease (Disorder) | scheduled | "NCT07285655 (A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07 (ESTIMATED); Lead Sponsor Liquidia Technologies, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07285655)) |
| Jul to Oct 2029 | [L606 topline data readout](https://sec-api.dev/pdufa/l606) | LQDA | Pulmonary Hypertension Due to Lung Disease (Disorder) | scheduled | "NCT07285655 (A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07 (ESTIMATED); Lead Sponsor Liquidia Technologies, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07285655)) |

## Drugs

- [DPI (dpi)](https://sec-api.dev/pdufa/dpi): 
- [L606](https://sec-api.dev/pdufa/l606): Pulmonary Hypertension Due to Lung Disease (Disorder)
- [Liq861 inhaled treprostinil](https://sec-api.dev/pdufa/liq861-inhaled-treprostinil): Primary Pulmonary Hypertension
- [Liq861 (treprostinil) inhalation powder - dose titration arm](https://sec-api.dev/pdufa/liq861-treprostinil-inhalation-powder-dose-titration-arm): Raynaud's Phenomenon Secondary to Systemic Sclerosis

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/lqda/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "LQDA catalysts: Liquidia Corp PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/lqda/catalysts

```bibtex
@misc{secapidev_companies_lqda_catalysts_20261116,
  title        = {LQDA catalysts: Liquidia Corp PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/lqda/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_lqda_catalysts_20261116","title":"LQDA catalysts: Liquidia Corp PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/lqda/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
